Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer

Laboratory Investigation

Volumn 82, Issue 11, 2002, Pages 1591-1598

  Hyytinen, Eija R ^a   Haapala, Kyllikki ^a   Thompson, James ^b   Lappalainen, Ilkka ^b,c   Roiha, Mikko ^a   Rantala, Immo ^a   Helin, Heikki J ^a   Jänne, Olli A ^b,d   Vihinen, Mauno ^a,c   Palvimo, Jorma J ^b   Koivisto, Pasi A ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMINO ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; DNA; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MISSENSE MUTATION; ORCHIECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM;

ESTRAMUSTINE; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 0036847896     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000038924.67707.75     Document Type: Article

References (52)

1. Adeyemo O, Kallio PJ, Palvimo JJ, Kontula K, and Jänne OA (1993). A single-base substitution in exon 6 of the androgen receptor gene causing complete androgen insensitivity: The mutated receptor fails to transactivate but binds to DNA in vitro. Hum Mol Genet 2:1809-1812.
2. Ahmed SF, Cheng A, Dovey L, Hawkins JR, Martin H, Rowland J, Shimura N, Tait AD, and Hughes IA (2000). Phenotypic features androgen receptor binding and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 85:658-665.
3. Andersen CL, Hostetter G, Grigoryan A, Sauter G, and Kallioniemi A (2001). Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 45:83-86.
4. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, and Kallioniemi OP (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806.
5. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, and Tilley WD (2001). Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281.
6. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, and Klocker H (1993). Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens an progesterone. Mol Endocrinol 7:1541-1550.
7. Dennis LJ and Griffiths K (2000). Endocrine treatment in prostate cancer. Semin Surg Oncol 18:52-74.
8. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, and Vihko P (1995). Mutated human androgen receptor gene detected in a prostatic cancer patients is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500.
9. Evans BAJ, Harper ME, Daniels CE, Watts CE, Matenhelia S, Green J, and Griffiths K (1996). Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 28:162-171.
10. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, and Srivastava S (1994). Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864.
11. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, and Lifton RP (2000). Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:23-26.
12. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, and Wilson EM (2001). A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
13. Grossmann ME, Huang H, and Tindall DJ (2001). Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
14. Haapala K, Hyytinen E-R, Roiha M, Laurila M, Rantala I, Helin HJ, and Koivisto PA (2001). Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 81: 1647-1651.
15. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, and Greenberg NM (2001). Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276:11204-11213.
16. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, and Kruse K (1998). Inherited and de novo androgen receptor gene mutations: Investigation of single-case families. J Pediatr 132:939-943.
17. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, and Coetzee GA (2000). Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9:267-274.
18. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, and Baretton GB (2000). FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80:1455-1464.
19. Karvonen U, Kallio PJ, Jänne OA, and Palvimo JJ (1997). Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J Biol Chem 272:15973-15979.
20. Kazemi-Esfarjani P, Beitel LK, Trifiro M, Kaufman M, Rennie P, Sheppard P, Matusik R, and Pinsky L (1993). Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity respectively with distinct androgen receptor phenotypes. Mol Endocrinol 7:37-46.
21. Koivisto P, Kolmer M, Visakorpi T, and Kallioniemi OP (1998). Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152:1-9.
22. Koivisto P, Kononen J, Palmberg C, Hyytinen E, Tammela T, Trapman J, Isola J, Visakorpi T, and Kallioniemi O-P (1997). Androgen receptor gene amplification: A possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 57:314-319.
23. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi O-P (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847.
24. Kuhn MW, Weissbach L, and Hinke A (1994). Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group. Urology 43(Suppl):61-67.
25. Lovell SC, Word JM, Richardson JS, and Richardson DC (2000). The penultimate rotamer library. Proteins 40:389-408.
26. Lubahn DB, Brown TR, Simental JA, Higgs HN, Migeon CJ, Wilson EM, and French FS (1989). Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci USA 86:9534-9538.
27. Määttänen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, and Hakama M (1999). European randomized study of prostate cancer screening: First-year results of the Finnish trial. Br J Cancer 79:1210-1214.
28. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, and Lamb DJ (2000). Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949.
29. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, and Carrondo MA (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor: Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171.
30. Mitchell S, Abel P, Ware M, Stamp G, and Lalani E (2000). Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 85:932-944.
31. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, Kitamura H, Koizumi Y, and Kubota Y (2000). Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43:225-232.
32. Mononen N, Syrjäkoski K, Matikainen M, Tammela TL, Schleutker J, Kallioniemi OP, Trapman J, and Koivisto PA (2000). Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 60:6479-6481.
33. Murphy GP, Huben RP, and Priore R (1986). Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40.
34. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, and Jänne OA (1996). Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 271: 24151-24156.
35. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, and van der Kwast TH (1994). Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746.
36. Scardino PT, Beck JR, and Miles BJ (1994). Conservative management of prostate cancer. N Engl J Med 330:1831.
37. 24◆8) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Comm 198:74-80.
38. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, and Shimazaki J (1996). Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 29:153-158.
39. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, and Shimazaki J (1993). Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765.
40. Tan I, Hall SH, Hamil KG, Grossman G, Petrusz P, Liao L, Shuai K, and French ES (2000). Protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1) is a nuclear receptor coregulator expressed in human testis. Mol Endocrinol 14:14-26.
41. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, and Balk SP (1999). Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
42. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, and Keer HN (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
43. Thompson J, Saatcioglu F, Jänne OA, and Palvimo JJ (2001). Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol 15:923-935.
44. Tilley WD, Buchanan G, Hickey TE, and Bentel JM (1996). Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
45. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, and Kallioniemi O-P (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
46. Wallen MJ, Linja M, Kaartinen K, Schleutker J, and Visakorpi T (1999). Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 189:559-563.
47. Wang LG, Liu XM, Kreis W, and Budman DR (1998). Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol 55:1427-1433.
48. Wang LG, Liu XM, Kreis W, and Budman DR (1999). Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 259:21-28.
49. Weidemann W, Linck B, Haupt H, Mentrup B, Romalo G, Stockklauser K, Brinkmann AO, Schweikert HU, and Spindler KD (1996). Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene. Clin Endocrinol 45:733-739.
50. Word JM, Bateman RC Jr, Presley BK, Lovell SC, and Richardson DC (2000). Exploring steric constraints on protein mutations using MAGE/PROBE. Protein Sci 11:2251-2259.
51. Yamamoto A, Hashimoto T, Kohri K, Ogata E, Kato S, Ikeda K, and Nakanishi M (2000). Cyclin E as a coactivator of the androgen receptor. J Cell Biol 150:873-880.
52. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, and Feldman D (2000). Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706.